| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5866591 | MYLAN INSTITUTIONAL | Stable formulations of remifentanil |
Sep, 2017
(6 years ago) | |
|
US5866591 (Pediatric) | MYLAN INSTITUTIONAL | Stable formulations of remifentanil |
Mar, 2018
(6 years ago) | |
Ultiva is owned by Mylan Institutional.
Ultiva contains Remifentanil Hydrochloride.
Ultiva has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Ultiva are:
- US5866591
- US5866591*PED
Ultiva was authorised for market use on 12 July, 1996.
Ultiva is available in injectable;injection dosage forms.
The generics of Ultiva are possible to be released after 10 March, 2018.
Drugs and Companies using REMIFENTANIL HYDROCHLORIDE ingredient
Market Authorisation Date: 12 July, 1996
Treatment: NA
Dosage: INJECTABLE;INJECTION
How can I launch a generic of ULTIVA before it's drug patent expiration?
More Information on Dosage
ULTIVA family patents
